Association between the BCR-ABL gene transcripts and the laboratory hematological profile

• Main Authors: Marcelo Braga de Oliveira (Author), Carolina de Alcântara Maneschy (Author), Jairo Augusto Américo de Castro (Author), Katarine Antonia dos Santos Barile (Author), Maurício Koury Palmeira (Author), Carlos Eduardo de Melo Amaral (Author)
• Format: Book
• Published: Hospital de Clínicas de Itajubá, 2022-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary

Objective: This study describes the hematological parameters associated with the BCR-ABL gene transcripts in patients with chronic myeloid leukemia (CML). Methods: We reviewed the results of 100 detectable patients for one of the BCR-ABL gene transcripts. The eligibility criteria were based on the presence of one of the leukemic transcripts (b2a2, b3a2, and b2a2/b3a2) and complete epidemiological and hematological data. The data were obtained from the LabMaster computerized system. The Kruskal-Wallis test was used to compare the medians of the quantitative variables between the transcripts of the BCR-ABL gene and the chi-square test to compare the qualitative ones, adopting the p-value with a level of significance less than or equal to 0.05. Results: Forty-five patients (45%) presented the b2a2 transcript, 24 (24%) the b3a2 transcript and 31 (31%) a b2a2/b3a2 coexpression. Individuals who expressed the b3a2 transcript had higher leukocyte counts and platelet levels, but we found no differences compared with individuals who expressed the other transcript. Conclusion: In this study, the BCR-ABL gene transcripts did not influence the hematological parameters of patients with CML.

Item Description

2236-3785
10.21876/rcshci.v12i3.1281